ArticleJTO clinical and research reports2025

AdvanTIG-204: A Phase 2, Randomized, Open-Label Study of Ociperlimab Plus Tislelizumab and Concurrent Chemoradiotherapy Versus Tislelizumab and Concurrent Chemotherapy Versus Concurrent Chemoradiotherapy in First-Line Limited-Stage SCLC.

Youling Gong et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.